Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00364429
Status:
TERMINATED
Last Update Posted:
2016-01-11
First Post:
2006-08-11
Brief Title:
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Investigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia a 123I-CNS 1261 Single Photon Emission Tomography SPET Study
Status:
TERMINATED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
terminated
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to compare the 123I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients Investigation of the potential influence of antipsychotic and concomitant medication on 123I CNS 1261 binding is also relevantFifteen healthy subjects male and female of non-child bearing potential will be recruited and 40 schizophrenic patients divided in 3 subgroups as indicated before Subgroup a treatment-naive n10 Subgroup b on stable treatment with risperidone without criteria of deficit syndrome on the SDS scale n15Subgroup c on stable treatment with risperidone fitting criteria of deficit syndrome on the SDS scale n15
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None